Prescient Therapeutics furthers development of novel anti-cancer targeted therapies

Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s development activities and plans for its novel targeted anti-cancer therapies.

The company recently locked-in US Food and Drug Administration orphan drug status for lead candidate PTX-100 in treating T-cell lymphomas where clinical trials are showing promising results.

Prescient has also topped up its cash reserves with $11.3 million raised to fund further development across its portfolio.

Articles:
https://smallcaps.com.au/prescient-therapeutics-ptx-100-promising-results-clinical-t-cell-lymphoma-trial/
https://smallcaps.com.au/prescient-therapeutics-fda-orphan-drug-status-ptx-100-treat-t-cell-lymphomas/

For more information on Prescient Therapeutics:
https://smallcaps.com.au/stocks/PTX/

-----------------------

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

-----------------------

WEBSITE
https://smallcaps.com.au/

PODCAST
https://smallcaps.com.au/podcast/

SOCIAL MEDIA
Facebook: https://www.facebook.com/SmallCapsASX
Twitter: https://twitter.com/SmallCapsASX
LinkedIn: https://www.linkedin.com/company/small-caps/

NEWSLETTER
https://smallcaps.com.au/subscribe/